• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Nancy U. Lin, MD


  • Lin NU, Thomssen C, Cardoso F, Cameron D, Cufer T, Fallowfield L, Francis PA, Kyriakides S, Pagani O, Senkus E, Costa A, Winer EP, .International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force: Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer.Breast. 2013 Apr 16.
  • Modi S, Saura C, Henderson C, Lin NU, Mahtani R, Goddard J, Rodenas E, Hudis C, O'Shaughnessy J, Baselga J.A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer.Breast Cancer Res Treat. 2013 Apr 12.
  • Olson EM, Najita JS, Sohl J, Arnaout A, Burstein HJ, Winer EP, Lin NU.Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era.Breast. 2013 Jan 23.
  • Mayer EL, Lin NU.Long term follow-up of national surgical adjuvant breast and bowel project trial B-31: how well can we predict cardiac toxicity with trastuzumab?.J Clin Oncol. 2012 Nov 1;30(31):3769-72.
  • Lin NU, Vanderplas A, Hughes ME, Theriault RL, Edge SB, Wong YN, Blayney DW, Niland JC, Winer EP, Weeks JC.Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network.Cancer. 2012 Nov 15;118(22):5463-72.
  • Arvold ND, Oh KS, Niemierko A, Taghian AG, Lin NU, Abi-Raad RF, Sreedhara M, Harris JR, Alexander BM.Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype.Breast Cancer Res Treat. 2012 Nov;136(1):153-60.
  • Vaz-Luis I, Ottesen RA, Hughes ME, Marcom PK, Moy B, Rugo HS, Theriault RL, Wilson J, Niland JC, Weeks JC, Lin NU.Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study.Breast Cancer Res. 2012 Oct 1;14(5):R129.
  • Joffe H, Deckersbach T, Lin NU, Makris N, Skaar TC, Rauch SL, Dougherty DD, Hall JE.Metabolic activity in the insular cortex and hypothalamus predicts hot flashes: an FDG-PET study.J Clin Endocrinol Metab. 2012 Sep;97(9):3207-15.
  • Whitesell L, Santagata S, Lin NU.Inhibiting HSP90 to treat cancer: a strategy in evolution.Curr Mol Med. 2012 Jul 17.
  • Dyer MA, Kelly PJ, Chen YH, Pinnell NE, Claus EB, Lee EQ, Weiss SE, Arvold ND, Lin NU, Alexander BM.Importance of extracranial disease status and tumor subtype for patients undergoing radiosurgery for breast cancer brain metastases.Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):e479-86.
  • Lin NU, Burstein HJ.EMBRACE, eribulin, and new realities of advanced breast cancer.Lancet. 2011 Mar 12;377(9769):878-80.
  • Morris PG, Chen C, Steingart RM, Fleisher M, Lin NU, Moy B, Come S, Sugarman S, Abbruzzi A, Lehman R, Patil S, Dickler MN, McArthur HL, Winer EP, Norton L, Hudis C, Dang CT.Troponin I and C-Reactive Protein are Commonly Detected in Patients with Breast Cancer Treated with Dose-Dense Chemotherapy Incorporating Trastuzumab and Lapatinib.Clin Cancer Res. 2011 Mar 3.
  • Lin NU, Winer EP.Chemotherapy agents in human epidermal growth factor receptor 2-positive breast cancer: time to step out of the limelight.J Clin Oncol. 2011 Jan 20;29(3):251-3.
  • Lin NU.Concordance of HER2 in primary tumor and leptomeningeal metastases: now what?.Breast Cancer Res Treat. 2010 Aug;123(1):129-31.
  • Morris PG, Dickler M, McArthur HL, Traina T, Sugarman S, Lin N, Moy B, Come S, Godfrey L, Nulsen B, Chen C, Steingart R, Rugo H, Norton L, Winer E, Hudis CA, Dang CT.Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction.J Clin Oncol. 2009 Dec 20;27(36):6117-23.
  • Lin NU, Kasparian E, Morganstern DE, Beard C.Geographic distribution of lapatinib-induced skin rash: sparing of abdominal skin persists in the transverse rectus abdominis myocutaneous flap.J Clin Oncol. 2009 Dec 1;27(34):e218-9.
  • Lin NU,Dieras V,Paul D,Lossignol D,Christodoulou C,Stemmler HJ,Roche H,Liu MC,Greil R,Ciruelos E,Loibl S,Gori S,Wardley A,Yardley D,Brufsky A,Blum JL,Rubin SD,Dharan B,Steplewski K,Zembryki D,Oliva C,Roychowdhury D,Paoletti P,Winer EP.Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.Clin Cancer Res. 2009 Feb 15;15(4):1452-9.
  • Lin NU,Claus E,Sohl J,Razzak AR,Arnaout A,Winer EP.Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases.Cancer. 2008 Nov 15;113(10):2638-45.
  • Chen RC,Lin NU,Golshan M,Harris JR,Bellon JR.Internal mammary nodes in breast cancer: diagnosis and implications for patient management -- a systematic review.J Clin Oncol. 2008 Oct 20;26(30):4981-9. Review.
  • Lin NU, Carey LA, Liu MC, Younger J, Come SE, Ewend M, Harris GJ, Bullitt E, Van den Abbeele AD, Henson JW, Li X, Gelman R, Burstein HJ, Kasparian E, Kirsch DG, Crawford A, Hochberg F, Winer EP.Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer.J Clin Oncol. 2008 Apr 20;26(12):1993-9.
  • Lin NU, Winer EP.Optimizing endocrine therapy for estrogen receptor-positive breast cancer: treating the right patients for the right length of time.J Clin Oncol. 2008 Apr 20;26(12):1919-21.
  • Lin NU, Winer EP.Advances in adjuvant endocrine therapy for postmenopausal women.J Clin Oncol. 2008 Feb 10;26(5):798-805. Review.
  • Liu MC, Demetri GD, Berry DA, Norton L, Broadwater G, Robert NJ, Duggan D, Hayes DF, Henderson IC, Lyss A, Hopkins J, Kaufman PA, Marcom PK, Younger J, Lin N, Tkaczuk K, Winer EP, Hudis CA.Dose-escalation of filgrastim does not improve efficacy: Clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel.Cancer Treat Rev. 2008 May;34(3):223-230.
  • Razzak AR, Lin NU, Winer EP.Heterogeneity of breast cancer and implications of adjuvant chemotherapy.Breast Cancer. 2008;15(1):31-4.
  • Bullitt E, Lin NU, Smith JK, Zeng D, Winer EP, Carey LA, Lin W, Ewend MG.Blood vessel morphologic changes depicted with MR angiography during treatment of brain metastases: a feasibility study.Radiology. 2007 Dec;245(3):824-30.
  • Lin NU, Winer EP.Optimal use of aromatase inhibitors: to lead or to follow?.J Clin Oncol. 2007 Jul 1;25(19):2639-41.
  • Lin NU, Parker LM, Come SE, Burstein HJ, Haldoupis M, Ryabin N, Gelman R, Winer EP, Shulman LN.Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions.Invest New Drugs. 2007 Aug;25(4):369-75.
  • Lin NU, Winer EP.Brain metastases: the HER2 paradigm.Clin Cancer Res. 2007 Mar 15;13(6):1648-55. Review.
  • Harris LN, Broadwater G, Lin NU, Miron A, Schnitt SJ, Cowan D, Lara J, Bleiweiss I, Berry D, Ellis M, Hayes DF, Winer EP, Dressler L.Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342.Breast Cancer Res. 2006;8(6):R66.
  • Lin NU, Bellon JR, Winer EP.CNS metastases in breast cancer.J Clin Oncol. 2004 Sep 1;22(17):3608-17.